Serbia registers 38 biosimilars; Europe total 161

Serbia has 38 registered biosimilars, compared to 161 in Europe, indicating a narrower market access. The gap suggests potential delays in regulatory approvals or market entry, which may affect patient access and healthcare costs. The data is from ALIMS, the Serbian medicines agency.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works